Patents by Inventor Masakuni KURONO

Masakuni KURONO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11512087
    Abstract: The present invention relates to a compound represented by general formula (I) (wherein, all symbols represent the same meanings as the symbols set forth in the specification), a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug of any of these. Since the compound has a Brk inhibitory activity, the compound is useful as a drug ingredient for the prevention and/or treatment of Brk-related diseases such as cancer, for example.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: November 29, 2022
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo Yamamoto, Hiroshi Tokura, Masakuni Kurono, Yoshinori Nomura, Shingo Hotta
  • Publication number: 20220306640
    Abstract: A compound of formula (I-a): wherein the symbols are defined in the specification, and which has a strong DDR1 inhibitory activity, and can be a therapeutic agent for DDR1-related diseases, for example, a cancer, a kidney disease, a cardiovascular disease, a central nervous system disease, or fibrosis.
    Type: Application
    Filed: September 4, 2020
    Publication date: September 29, 2022
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Yota NISHIOKA, Masakuni KURONO, Rena NISHIZAWA, Balachandra BANDODKAR, Xuechao GAO, Zhilong WAN, Ranran LV, Kevin DOYLE, Michael GOLDSMITH
  • Publication number: 20210363166
    Abstract: A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1): wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.
    Type: Application
    Filed: August 6, 2021
    Publication date: November 25, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Ryosuke HANADA, Masaya KOKUBO, Masakuni KURONO, Kenichi KOUDA, Hiroshi HAGIYA
  • Patent number: 11130773
    Abstract: A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1): wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: September 28, 2021
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Ryosuke Hanada, Masaya Kokubo, Masakuni Kurono, Kenichi Kouda, Hiroshi Hagiya
  • Publication number: 20210253615
    Abstract: A drug or agent containing a compound having an agonistic activity to STING as an active ingredient, where the compound is represented by the following general formula (I-1): wherein all symbols represent the same meanings as described in the specification, and the compound can be used as an active ingredient of an agent for suppressing the progression of, suppressing the recurrence of and/or treating cancer or infectious disease.
    Type: Application
    Filed: October 10, 2019
    Publication date: August 19, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Ryosuke HANADA, Masaya KOKUBO, Masakuni KURONO, Kenichi KOUDA, Hiroshi HAGIYA
  • Patent number: 11052091
    Abstract: The present invention relates to a Brk inhibitory compound represented by general formula (I) (wherein, all symbols represent the same meanings as the symbols set forth in the specification), a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug of any of these.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: July 6, 2021
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo Yamamoto, Masakuni Kurono, Atsushi Yoshida, Shingo Hotta
  • Publication number: 20200000810
    Abstract: The present invention relates to a Brk inhibitory compound represented by general formula (I) (wherein, all symbols represent the same meanings as the symbols set forth in the specification), a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug of any of these.
    Type: Application
    Filed: December 20, 2017
    Publication date: January 2, 2020
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo YAMAMOTO, Masakuni KURONO, Atsushi YOSHIDA, Shingo HOTTA
  • Publication number: 20190315756
    Abstract: The present invention relates to a compound represented by general formula (I) (wherein, all symbols represent the same meanings as the symbols set forth in the specification), a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug of any of these. Since the compound has a Brk inhibitory activity, the compound is useful as a drug ingredient for the prevention and/or treatment of Brk-related diseases such as cancer, for example.
    Type: Application
    Filed: June 27, 2019
    Publication date: October 17, 2019
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo YAMAMOTO, Hiroshi TOKURA, Masakuni KURONO, Yoshinori NOMURA, Shingo HOTTA
  • Patent number: 10377759
    Abstract: The present invention relates to a compound represented by general formula (I) (wherein, all symbols represent the same meanings as the symbols set forth in the specification), a salt thereof, a solvate thereof, an N-oxide thereof, or a prodrug of any of these. Since the compound has a Brk inhibitory activity, the compound is useful as a drug ingredient for the prevention and/or treatment of Brk-related diseases such as cancer, for example.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: August 13, 2019
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo Yamamoto, Hiroshi Tokura, Masakuni Kurono, Yoshinori Nomura, Shingo Hotta
  • Publication number: 20180186800
    Abstract: The present invention relates to a compound represented by general formula (I) (wherein, all symbols represent the same meanings as the symbols set forth in the specification), a salt thereof, a solvate thereof an N-oxide thereof, or a prodrug of any of these. Since the compound has a Brk inhibitory activity, the compound is useful as a drug ingredient for the prevention and/or treatment of Brk-related diseases such as cancer, for example.
    Type: Application
    Filed: June 21, 2016
    Publication date: July 5, 2018
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo YAMAMOTO, Hiroshi TOKURA, Masakuni KURONO, Yoshinori NOMURA, Shingo HOTTA
  • Publication number: 20180089363
    Abstract: A method for extracting a lead compound from a plurality of compounds against a drug discovery target, includes the steps of creating a scatter diagram for a plurality of compounds by disposing symbols representing the compounds according to a plurality of features of the compounds and extracting a lead compound from the compounds represented by the symbols disposed in a predetermined region of the scatter diagram. The locations of the symbols to be disposed on the scatter diagram are determined according to first and second features (for example, selectivity and activity) of the respective compounds, and attributes (for example, color and size) of the symbols are determined according to third and fourth features (for example, molecular weight and ligand efficiency) of the respective compounds.
    Type: Application
    Filed: April 21, 2016
    Publication date: March 29, 2018
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Masakuni KURONO, Hiromu EGASHIRA, Jun TAKEUCHI